Keros Therapeutics, Inc. (KROS)
NASDAQ:KROS
Want to see KROS full AI Analyst Report?
KROS Stock Chart & Stats
$11.67
-$0.58(-3.66%)
At close: 4:00 PM EST
$11.67
-$0.58(-3.66%)
Day’s Range― - ―
52-Week Range$9.69 - $22.55
Previous CloseN/A
Volume109.28K
Average Volume (3M)300.21K
Market Cap
$210.78M
Enterprise Value$67.91M
Total Cash (Recent Filing)$281.50M
Total Debt (Recent Filing)$16.31M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
Aug 12, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding19,791,838
10 Day Avg. Volume214,024
30 Day Avg. Volume300,210
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit2.12
Enterprise Value/Ebitda-0.77
Forecast
1Y Price Target
$19.00Price Target Upside62.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)-6
Revenue Forecast (FY)$4.24M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthKeros' very low leverage and modest absolute debt provide durable financial flexibility during multi-year clinical development. Low interest burden and a conservative capital structure reduce near-term solvency risk and give management optionality to fund trials, partnerships, or selective asset investments without high debt pressure.
Platform-based TGF-β TherapeuticsA platform approach targeting TGF-β family signaling creates R&D leverage across neuromuscular and hematologic indications. Durable advantages include shared discovery infrastructure, repeatable molecule engineering, and the ability to pursue multiple indications, which spreads technical risk and enhances long-term partnership potential.
Strategic ALS CollaborationThe Healey ALS MyMatch collaboration secures access to biomarker-driven cohorts and high-enrolling U.S. centers, improving trial design and enrollment durability. Structural access to a specialized network accelerates clinical de-risking, increases data quality, and strengthens future partnership or licensing discussions for rinvatercept.
Bears Say
Negative Cash Flow / Cash GenerationA swing to materially negative operating and free cash flow in the TTM period represents a structural challenge for a development-stage biotech. Persistent cash burn requires recurring financing or partner funding, raising dilution risk, forcing program prioritization, and constraining the company’s ability to advance multiple trials simultaneously.
Volatile Revenue And Return To LossesRevenue and profitability have been highly lumpy, with a sharp drop from 2025 levels to TTM and a return to sizable losses. This episodic income pattern undermines predictability for R&D funding and operational planning, making multi-period investment and hiring decisions riskier for sustaining clinical programs.
Dependence On Collaboration/Milestone RevenueKeros relies primarily on collaboration payments and milestone-triggered recognition rather than recurring product sales. Structurally, this creates lumpy cash flows tied to partner milestones and regulatory events, increasing execution risk and the likelihood of external financing that can dilute shareholders if development timelines slip.
Keros Therapeutics News
KROS FAQ
What was Keros Therapeutics, Inc.’s price range in the past 12 months?
Keros Therapeutics, Inc. lowest stock price was $9.69 and its highest was $22.55 in the past 12 months.
What is Keros Therapeutics, Inc.’s market cap?
Keros Therapeutics, Inc.’s market cap is $210.78M.
When is Keros Therapeutics, Inc.’s upcoming earnings report date?
Keros Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 53 days.
How were Keros Therapeutics, Inc.’s earnings last quarter?
Keros Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$1.21 earnings per share for the quarter, missing the consensus estimate of -$1.023 by -$0.187.
Is Keros Therapeutics, Inc. overvalued?
According to Wall Street analysts Keros Therapeutics, Inc.’s price is currently Undervalued.
Does Keros Therapeutics, Inc. pay dividends?
Keros Therapeutics, Inc. does not currently pay dividends.
What is Keros Therapeutics, Inc.’s EPS estimate?
Keros Therapeutics, Inc.’s EPS estimate is -1.34.
How many shares outstanding does Keros Therapeutics, Inc. have?
Keros Therapeutics, Inc. has 19,791,838 shares outstanding.
What happened to Keros Therapeutics, Inc.’s price movement after its last earnings report?
Keros Therapeutics, Inc. reported an EPS of -$1.21 in its last earnings report, missing expectations of -$1.023. Following the earnings report the stock price went down -8.34%.
Which hedge fund is a major shareholder of Keros Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KROS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keros Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (62.81% Upside)
$19.00 (62.81% Upside)
Blogger Sentiment
Bullish
KROS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 42.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.3%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.40%
12-Months-Change
Fundamentals
Return on Equity
-17.04%
Trailing 12-Months
Asset Growth
-60.20%
Trailing 12-Months
Company Description
Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
KROS Stock 12 Month Forecast
Average Price Target
$19.00
▲(62.81% Upside)
Technical Analysis
Gyre Therapeutics
―
―
Palvella Therapeutics
―
Nurix Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
4.94% Insiders
19.25% Mutual Funds
22.98% Other Institutional Investors
36.32% Public Companies and
Individual Investors